Plus Therapeutics, Inc.

As of August 14, 2023, Plus Therapeutics, Inc. has been downgraded to a risky valuation grade due to negative financial ratios and significant underperformance, with a year-to-date return of -62.51% compared to the S&P 500's 12.22%.

As of August 14, 2023, Plus Therapeutics, Inc. is considered risky and overvalued due to negative financial metrics, including a price-to-book value of -0.45 and an EV to EBITDA ratio of -0.06, alongside a year-to-date return of -83.97%, significantly underperforming compared to its peers and the S&P 500.

As of June 18, 2025, the technical trend has shifted to bearish, indicated by negative signals from the MACD, moving averages, and Bollinger Bands, despite a bullish monthly OBV.

As of March 2022, the management team of Plus Therapeutics, Inc. includes Chairman Richard Hawkins, CEO Dr. Marc Hedrick, and Independent Directors Howard Clowes, Robert Lenk, Greg Petersen, and Annigje van Es-Johansson, who oversee the company's strategic direction and operations.

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing cancer treatments, with a market cap of $10.18 million and recent quarterly net sales of $1 million and a net loss of $17 million.

As of Jun 18, Plus Therapeutics, Inc. has a market capitalization of 10.18 million, with net sales of 5.21 million and a net profit of -27.11 million over the last four quarters. The company reported shareholder's funds of -8.95 million and total assets of 6.63 million as of Dec 24.